Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708612 | 0.93 | TAS1R3 (0.32) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL21708613 | 0.92 | TAS1R3 (0.33) | PTGFR | |
| SCHEMBL21708602 | 0.90 | SMN1; SMN2 (0.33) | PTGFRKMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL21708615 | 0.87 | PTGFR (0.35) | PTGFRKMT2AMEN1 | |
| SCHEMBL21708507 | 0.86 | PTGFR (0.33) | PTGFRKMT2AMEN1 | |
| SCHEMBL21708481 | 0.85 | GAA (0.32) | PTGFRL3MBTL1 | |
| SCHEMBL21708491 | 0.85 | PTGFR (0.37) | PTGFR | |
| SCHEMBL21708580 | 0.85 | KMT2A (0.34) | KMT2AHPGDALDH1A1MEN1LMNA | |
| SCHEMBL21708464 | 0.84 | PTGFR (0.35) | PTGFRALDH1A1L3MBTL1KDM4E | |
| SCHEMBL21708792 | 0.82 | TAS1R3 (0.33) | KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |